Endolymphatic Radiotherapy in Maglignant Lymphomas

· ·
· Recent Results in Cancer Research āļŦāļ™āļąāļ‡āļŠāļ·āļ­āđ€āļĨāđˆāļĄāļ—āļĩāđˆ 37 · Springer Science & Business Media
eBook
132
āļŦāļ™āđ‰āļē
āļ„āļ°āđāļ™āļ™āđāļĨāļ°āļĢāļĩāļ§āļīāļ§āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļ•āļĢāļ§āļˆāļŠāļ­āļšāļĒāļ·āļ™āļĒāļąāļ™ Â āļ”āļđāļ‚āđ‰āļ­āļĄāļđāļĨāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āđ€āļāļĩāđˆāļĒāļ§āļāļąāļš eBook āđ€āļĨāđˆāļĄāļ™āļĩāđ‰

Clinical trials with Lipiodol l3ll were started in 1961 by my associate, S. CHIAPPA, and a group of physicians at the Institute of Radiology and the National Cancer Institute in Milan and development has been vigorously pursued during the past years. Once the rationale of this method was established, various aspects of the prob lem have been investigated, particularly the distribution of the radioactive dye into the lymph nodes as weIl as its fate and dosimetry in the body tissues. This mono graph describes the extensive clinical evaluation and the radiological results obtained in a large group of patients with malignant lymphomas. Endolymphatic radiotherapy as a therapeutic tool employing radiÃķnuclides has aroused interest at several meetings concerned with lymphology. In the re cent mono graph "Lymphography in cancer" by W. A. FUCHS, J. W. DAVIDSON and H. W. FISCHER, Dr. JANTET wrote a chapter on this specific subject. Many aspects are still debated, i. e. the choice of radionuclide, the specific clinical indications and the proper evaluation of the therapeutic effects. It is hoped that further studies will come to more precise conclusions.

āđƒāļŦāđ‰āļ„āļ°āđāļ™āļ™ eBook āļ™āļĩāđ‰

āđāļŠāļ”āļ‡āļ„āļ§āļēāļĄāđ€āļŦāđ‡āļ™āļ‚āļ­āļ‡āļ„āļļāļ“āđƒāļŦāđ‰āđ€āļĢāļēāļĢāļąāļšāļĢāļđāđ‰

āļ‚āđ‰āļ­āļĄāļđāļĨāđƒāļ™āļāļēāļĢāļ­āđˆāļēāļ™

āļŠāļĄāļēāļĢāđŒāļ—āđ‚āļŸāļ™āđāļĨāļ°āđāļ—āđ‡āļšāđ€āļĨāđ‡āļ•
āļ•āļīāļ”āļ•āļąāđ‰āļ‡āđāļ­āļ› Google Play Books āļŠāļģāļŦāļĢāļąāļš Android āđāļĨāļ° iPad/iPhone āđāļ­āļ›āļˆāļ°āļ‹āļīāļ‡āļ„āđŒāđ‚āļ”āļĒāļ­āļąāļ•āđ‚āļ™āļĄāļąāļ•āļīāļāļąāļšāļšāļąāļāļŠāļĩāļ‚āļ­āļ‡āļ„āļļāļ“ āđāļĨāļ°āļŠāđˆāļ§āļĒāđƒāļŦāđ‰āļ„āļļāļ“āļ­āđˆāļēāļ™āđāļšāļšāļ­āļ­āļ™āđ„āļĨāļ™āđŒāļŦāļĢāļ·āļ­āļ­āļ­āļŸāđ„āļĨāļ™āđŒāđ„āļ”āđ‰āļ—āļļāļāļ—āļĩāđˆ
āđāļĨāđ‡āļ›āļ—āđ‡āļ­āļ›āđāļĨāļ°āļ„āļ­āļĄāļžāļīāļ§āđ€āļ•āļ­āļĢāđŒ
āļ„āļļāļ“āļŸāļąāļ‡āļŦāļ™āļąāļ‡āļŠāļ·āļ­āđ€āļŠāļĩāļĒāļ‡āļ—āļĩāđˆāļ‹āļ·āđ‰āļ­āļˆāļēāļ Google Play āđ‚āļ”āļĒāđƒāļŠāđ‰āđ€āļ§āđ‡āļšāđ€āļšāļĢāļēāļ§āđŒāđ€āļ‹āļ­āļĢāđŒāđƒāļ™āļ„āļ­āļĄāļžāļīāļ§āđ€āļ•āļ­āļĢāđŒāđ„āļ”āđ‰
eReader āđāļĨāļ°āļ­āļļāļ›āļāļĢāļ“āđŒāļ­āļ·āđˆāļ™āđ†
āļŦāļēāļāļ•āđ‰āļ­āļ‡āļāļēāļĢāļ­āđˆāļēāļ™āļšāļ™āļ­āļļāļ›āļāļĢāļ“āđŒ e-ink āđ€āļŠāđˆāļ™ Kobo eReader āļ„āļļāļ“āļˆāļ°āļ•āđ‰āļ­āļ‡āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļĨāļ°āđ‚āļ­āļ™āđ„āļŸāļĨāđŒāđ„āļ›āļĒāļąāļ‡āļ­āļļāļ›āļāļĢāļ“āđŒāļ‚āļ­āļ‡āļ„āļļāļ“ āđ‚āļ›āļĢāļ”āļ—āļģāļ•āļēāļĄāļ§āļīāļ˜āļĩāļāļēāļĢāļ­āļĒāđˆāļēāļ‡āļĨāļ°āđ€āļ­āļĩāļĒāļ”āđƒāļ™āļĻāļđāļ™āļĒāđŒāļŠāđˆāļ§āļĒāđ€āļŦāļĨāļ·āļ­āđ€āļžāļ·āđˆāļ­āđ‚āļ­āļ™āđ„āļŸāļĨāđŒāđ„āļ›āļĒāļąāļ‡ eReader āļ—āļĩāđˆāļĢāļ­āļ‡āļĢāļąāļš